◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

LSL Pharma Group Inc. — SEDAR+ Filings

Open SEDAR+
All Annual Reports 3 Quarterly Reports 12 MD&A 16 News Releases 42 Material Changes 20 Certifications 45 Other 21
DocumentTypeFiling DatePeriodStatus
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf Other 25 Nov 2021 -- Failed
Report of exempt distribution (45-106F1) (amended).pdf Other 2026-01-14 -- PDF
Early warning report.pdf Other 2026-01-06 -- PDF
Report of exempt distribution (45-106F1).pdf Other 2026-01-02 -- PDF
NI 44-101 Notice of intent to qualify – English.pdf Other 2025-10-17 -- PDF
Report of exempt distribution (45-106F1).pdf Other 2025-09-08 -- PDF
Report of voting results.pdf Other 2025-06-27 -- PDF
Report of exempt distribution (45-106F1).pdf Other 2024-12-30 -- PDF
Notice.pdf Other 2024-09-25 -- PDF
Letter from former auditor.pdf Other 2024-09-25 -- PDF
Letter from successor auditor.pdf Other 2024-09-25 -- PDF
Report of exempt distribution (45-106F1).pdf Other 2024-07-22 -- PDF
Report of exempt distribution (45-106F1).pdf Other 2024-07-04 -- PDF
Report of exempt distribution (45-106F1).pdf Other 2023-12-15 -- PDF
Notice of the meeting and record date - English.pdf Other 2023-12-05 -- PDF
Notice of the meeting and record date - French.pdf Other 2023-12-05 -- PDF
Report of exempt distribution (45-106F1).pdf Other 2023-11-10 -- PDF
Documents affecting rights of securityholders - Trust indentures re debt.pdf Other 2023-11-03 -- PDF
Statement of executive compensation (form 51-102F6V) - French.pdf Other 2021-11-25 -- PDF
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf Other 2021-11-25 -- PDF
Statement of executive compensation (form 51-102F6V) - French.pdf Other 2021-11-25 -- PDF
NEWS
Loading news...
TRENDING
Loading...